Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies

Resource type
Journal Article
Authors/contributors
Title
Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies
Abstract
Febrile neutropenia (FN) is common among hematologic malignancy patients, including recipients of hematopoietic cell transplantation (HCT) and cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Prompt empiric antibiotic use has been the mainstay for decades but a “one-size-fits-all” approach is no longer broadly accepted, as treatment-related infectious risk are more understood. Growing antimicrobial resistance is an increasing clinical challenge. Evolving strategies on deescalation of broad-spectrum antibiotics in FN without identified infection are areas of particular interest.
Publication
Transplant Infectious Disease
Pages
e14236
Date
2024-02-13
Journal Abbr
Transplant Infectious Dis
Language
en
ISSN
1398-2273, 1399-3062
Accessed
3/17/24, 5:57 PM
Library Catalog
DOI.org (Crossref)
Citation
Stohs, E. J., Abbas, A., & Freifeld, A. (2024). Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. Transplant Infectious Disease, e14236. https://doi.org/10.1111/tid.14236
HEME-ONC AND CELLULAR THERAPIES
Link to this record